Zero Candida Technologies to Present at the OTCQB Venture Virtual Investor Conference on August 7th

Zero Candida Technologies, Inc. (TSXV: ZCT, OTCQB: ZCTFF) recently announced that its CFO, Sophya Galper Komet, and Founder Dr. Asher Holzer will present at the OTCQB Venture Virtual Investor Conference on August 7, 2025, at 12 PM ET. This online event will allow investors to engage with the Company's representatives and pose questions in real-time. For those unable to attend live, an archived webcast will be available after the conference. Interested participants are encouraged to pre-register for a smoother experience.

Zero Candida is a pioneering medical device company focused on women's health, specifically targeting Vulvo-Vaginal Candidiasis (VVC), which affects roughly 75% of women globally. Its innovative SMART, AI-driven device is designed to provide personalized at-home care, incorporating therapeutic blue light to effectively eliminate Candida in a matter of hours. With results showing a 99.999% Candida elimination during point-of-care testing, the company is targeting the FDA's De Novo regulatory pathway for approval.

In addition to expanding its global intellectual property portfolio—with patents filed in key markets like Europe and the U.S.—ZCT is also engaging in discussions with major U.S. hospitals and pharmaceutical companies to pave the way for future clinical trials and commercialization efforts. The company, which is also cross-listed on the Frankfurt Stock Exchange (FSE), has notably achieved recent DTC eligibility, thereby broadening its investor reach.

With the VVC treatment market projected to exceed $2 billion by 2030, Zero Candida aims to integrate hybrid medicine with technology-based diagnostics, advancing gynecological care into the 21st century. For more information, please visit their website at www.zero-candida.com.

Zero Candida Technologies, Inc. (ZCT), a notable player in the FemTech industry, is primed for significant attention at the upcoming OTCQB Venture Virtual Investor Conference scheduled for August 7, 2025. With the presentation led by CFO Sophya Galper Komet and founder Dr. Asher Holzer, the company's innovative approach to women's health could capture investor interest, especially given its recent achievements.

The data shared about ZCT's technology is promising; a reported 99.999% elimination of Candida in just three hours signifies a potential breakthrough in treating Vulvo-Vaginal Candidiasis (VVC). With a global treatment market for VVC projected to surpass $2 billion by 2030, this could position ZCT favorably within the investment community. The company is actively pursuing an FDA De Novo regulatory pathway, an essential step that could elevate its device to greater legitimacy and wider market access.

Investors should note ZCT's efforts to expand its intellectual property portfolio, including patents filed in key markets such as the U.S., Europe, and Brazil, which enhances its competitive positioning. Furthermore, the company’s DTC eligibility increases accessibility for American investors, paving the way for potential stock price appreciation.

With ongoing discussions with major hospitals and U.S. pharmaceutical companies, ZCT is strategically positioned for future clinical trials and commercialization, which could serve as catalysts for growth.

For investors considering ZCT, attending the conference or engaging in the 1x1 meetings can provide valuable insights and a firsthand opportunity to gauge the company’s strategic direction. Given its innovative technology, potential market size, and strategic partnerships, ZCT warrants a close watch as it navigates its growth trajectory in a rapidly evolving healthcare sector.